Otsuka (OTCMKTS:OTSKY) Stock Rating Lowered by Zacks Research

Otsuka (OTCMKTS:OTSKY) was downgraded by research analysts at Zacks Research from a “strong-buy” rating to a “hold” rating in a research report issued to clients and investors on Monday, Zacks reports.

Otsuka Stock Performance

Shares of OTSKY opened at $37.68 on Monday. The company has a market cap of $40.48 billion, a price-to-earnings ratio of 16.17, a P/E/G ratio of 2.75 and a beta of 0.08. The business’s fifty day simple moving average is $37.29 and its two-hundred day simple moving average is $35.15. Otsuka has a 12 month low of $26.11 and a 12 month high of $40.92. The company has a current ratio of 2.21, a quick ratio of 1.65 and a debt-to-equity ratio of 0.05.

Otsuka (OTCMKTS:OTSKY) last posted its quarterly earnings results on Friday, October 30th. The company reported $0.64 earnings per share for the quarter, topping the consensus estimate of $0.59 by $0.05. The firm had revenue of $4.51 billion during the quarter, compared to analysts’ expectations of $4.42 billion. Otsuka had a return on equity of 11.90% and a net margin of 14.36%. Research analysts anticipate that Otsuka will post 2.21 earnings per share for the current fiscal year.

About Otsuka

Otsuka Holdings Co., Ltd. is a Japan-based holding company whose businesses focus primarily on pharmaceuticals and nutraceuticals. Its group companies research, develop, manufacture, and market prescription medicines, consumer health products, and medical devices. Otsuka’s pharmaceutical portfolio includes treatments across areas such as mental health, kidney disease, and oncology. Its nutraceutical business offers products including Pocari Sweat and CalorieMate, alongside other nutrition and wellness products.